Article Information
History
- May 23, 2021.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Ang Lin, Ph.D.1,*,
- JingJing Liu, Ph.D.2,*,
- Xiaopin Ma, Ph.D.1,
- Fanfan Zhao, Ph.D.1,
- Bo Yu, M.D.1,
- Jiaxin He, M.Sc.1,
- Mingyun Shen, Ph.D.1,
- Lei Huang, M.Sc.1,
- Hongming Tang, M.D., Ph.D.3,
- Erpeng Jiang, M.D., Ph.D.3,
- Yue Wang, M.D.3,
- Pingfang Cui, Ph.D.4,
- Yujian Zhang, Ph.D.1,
- Weiguo Yao, M.D., Ph.D.1,
- Aihua Zhang, Ph.D.1,
- Youchun Wang2,
- Yuhua Li, Ph.D.2,#,
- Weijin Huang, Ph.D.2,#,
- Qihan Li, Ph.D.4,#,
- Zhongmin Liu, M.D., Ph.D.3,# and
- Hangwen Li, M.D., Ph.D.1,2,#
- 1Stemirna Therapeutics Inc., Pudong, Shanghai, China
- 2National Institutes for Food and Drug Control (NIFDC), Beijing, China
- 3Shanghai East Hospital, Tongji University, Shanghai China
- 4Institute of Medical Biology, Chinese Academy of Medical Sciences, Kunming, China
- ↵#Correspondence to:
Hangwen Li, lihangwen{at}stemirna.com; Zhongmin Liu, liu.zhongmin{at}tongji.edu.cn; Qihan Li, liqihan{at}imbcams.com.cn; Weijin Huang, huangweijin{at}nifdc.org.cn; Yuhua Li, liyuhua{at}nifdc.org.cn
↵* authors contributed equally